Table of Contents
ISRN Chromatography
Volume 2013, Article ID 878295, 8 pages
http://dx.doi.org/10.1155/2013/878295
Research Article

A Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Tenofovir, Emtricitabine, and a Efavirenz and Statistical Approach to Determine the Effect of Variables

1National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad 500037, India
2USP-India Private Limited, ICICI Knowledge Park, Shameerpet, Hyderabad 500078, India

Received 30 November 2012; Accepted 26 December 2012

Academic Editors: C. Akbay, G. K. Jayaprakasha, and C. M. Remsberg

Copyright © 2013 Prashant S. Devrukhakar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. UNAIDS, “AIDS epidemic update: December 2009. WHO Regional Office Europe,” http://www.unaids.org/en/dataanalysis/knowyourepidemic/epidemiologypublications/2009aidsepidemicupdate/.
  2. D. J. Porche, “Tenofovir disoproxil fumarate (Viread),” The Journal of the Association of Nurses in AIDS Care, vol. 13, no. 3, pp. 100–102, 2002. View at Google Scholar · View at Scopus
  3. H. B. Fung, E. A. Stone, and F. J. Piacenti, “Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection,” Clinical Therapeutics, vol. 24, no. 10, pp. 1515–1548, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. E. DeClercq and P. Tulkens, “Anti-infectives, editorial overview,” Current Opinion in Pharmacology, vol. 4, no. 5, pp. 429–430, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Van Bambeke, M. Barcia-Macay, S. Lemaire, and P. M. Tulkens, “Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives,” Current Opinion in Drug Discovery and Development, vol. 9, no. 2, pp. 218–230, 2006. View at Google Scholar · View at Scopus
  6. V. Jullien, J. M. Tréluyer, G. Pons, and E. Rey, “Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection,” Journal of Chromatography B, vol. 785, no. 2, pp. 377–381, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. N. L. Rezk, R. D. Crutchley, and A. D. M. Kashuba, “Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction,” Journal of Chromatography B, vol. 822, no. 1-2, pp. 201–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Delahunty, L. Bushman, and C. V. Fletcher, “Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS,” Journal of Chromatography B, vol. 830, no. 1, pp. 6–12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. E. Barkil, M. C. Gagnieu, and J. Guitton, “Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring,” Journal of Chromatography B, vol. 854, no. 1-2, pp. 192–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. N. A. Gomes, V. V. Vaidya, A. Pudage, S. S. Joshi, and S. A. Parekh, “Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 3, pp. 918–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. P. B. Kandagal, D. H. Manjunatha, J. Seetharamappa, and S. S. Kalanur, “RP-HPLC method for the determination of tenofovir in pharmaceutical formulations and spiked human plasma,” Analytical Letters, vol. 41, no. 4, pp. 561–570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Ashenafi, A. Verbeek, J. Hoogmartens, and E. Adams, “Development and validation of an LC method for the determination of emtricitabine and related compounds in the drug substance,” Journal of Separation Science, vol. 32, no. 11, pp. 1823–1830, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. W. Sparidans, K. M. L. Crommentuyn, J. H. M. Schellens, and J. H. Beijnen, “Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde,” Journal of Chromatography B, vol. 791, no. 1-2, pp. 227–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. U. Seshachalam, B. Haribabu, and K. B. Chandrasekhar, “Development and validation of a stability-indicating liquid chromatographic method for determination of emtricitabine and related impurities in drug substance,” Journal of Separation Science, vol. 30, no. 7, pp. 999–1004, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. R. P. Weissburg, E. R. Montgomery, L. A. Junnier, J. Segretario, S. Cook, and P. K. Hovsepian, “Investigation of critical factors for the resolution of SR695, a key impurity, from efavirenz in the reversed-phase assay of efavirenz dosage forms,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 1, pp. 45–56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Mogatle and I. Kanfer, “Rapid method for the quantitative determination of efavirenz in human plasma,” Journal of Pharmaceutical and Biomedical Analysis, vol. 49, no. 5, pp. 1308–1312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. R. Montgomery, A. L. Edmanson, S. C. Cook, and P. K. Hovsepian, “Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 25, no. 2, pp. 267–284, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. U. Seshachalam, D. V. L. Narasimha Rao, and K. B. Chandrasekhar, “Validated enantiospecific LC method for determination of (R)-enantiomer impurity in (S)-efavirenz,” Pharmazie, vol. 63, no. 2, pp. 107–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Joshi, A. P. Nikalje, M. Shahed, and M. Dehghan, “HPTLC method for the simultaneous estimation of emtricitabine and tenofovir in tablet dosage form,” Indian Journal of Pharmaceutical Sciences, vol. 71, no. 1, pp. 95–97, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Kaul, H. Agrawal, A. R. Paradkar, and K. R. Mahadik, “The international conference on harmonisation guidance in practice: stress degradation studies on lamivudine and development of a validated specific stability-indicating HPTLC assay method,” Chromatographia, vol. 60, no. 3-4, pp. 213–221, 2004. View at Google Scholar · View at Scopus
  21. N. A. Raju and S. Begum, “Simultaneous RP-HPLC method for the estimation of the emtricitabine, tenofovir disoproxil fumerate and efavirenz in tablet dosage forms,” Research Journal of Pharmacy and Technology, vol. 1, pp. 522–525, 2008. View at Google Scholar
  22. ICH guideline, “Q1A R2 stability testing of new drug substances and products,” in Proceedings of the International Conference on Harmonization, Food and Drug Administration, Rockville, Md, USA, February 2003.
  23. ICH guideline, “Q1B photostability testing on new drug substances and products,” in Proceedings of the International Conference on Harmonization, Food and Drug Administration, Rockville, Md, USA, 1996.
  24. ICH guideline, “Q2 R1 validation of analytical procedures: text and methodology,” in Proceedings of the International Conference on Harmonization, Food and Drug Administration, Rockville, Md, USA, November 2005.